메뉴 건너뛰기




Volumn 13, Issue 7, 2007, Pages 1961-1970

The potential of antiangiogenic therapy in non-small cell lung cancer

Author keywords

[No Author keywords available]

Indexed keywords

3 (4 BROMO 2,6 DIFLUOROBENZYLOXY) 5 [3 [4 (1 PYRROLIDINYL)BUTYL]UREIDO] 4 ISOTHIAZOLECARBOXAMIDE; 4 (4 FLUORO 2 METHYL 5 INDOLYLOXY) 6 METHOXY 7 [3 (1 PYRROLIDINYL)PROPOXY]QUINAZOLINE; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; ENZASTAURIN; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; INTERLEUKIN 2; IRINOTECAN; N (3,3 DIMETHYL 6 INDOLINYL) 2 (4 PYRIDINYLMETHYLAMINO)NICOTINAMIDE; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PEMETREXED; PLACEBO; RECOMBINANT VASCULOTROPIN; SORAFENIB; SUNITINIB; THALIDOMIDE; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN INHIBITOR; VATALANIB;

EID: 34247468303     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-2186     Document Type: Review
Times cited : (64)

References (102)
  • 3
    • 1342268525 scopus 로고    scopus 로고
    • American Society of Clinical Oncology treatment of unresectable non-small cell lung cancer guideline: Update 2003
    • Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small cell lung cancer guideline: update 2003. J Clin Oncol 2004;22:330-53.
    • (2004) J Clin Oncol , vol.22 , pp. 330-353
    • Pfister, D.G.1    Johnson, D.H.2    Azzoli, C.G.3
  • 5
    • 0037050352 scopus 로고    scopus 로고
    • Comparison of four chemotherapy regimens for advanced non-small cell lung cancer
    • Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 2002;346:92-8.
    • (2002) N Engl J Med , vol.346 , pp. 92-98
    • Schiller, J.H.1    Harrington, D.2    Belani, C.P.3
  • 6
    • 0037529167 scopus 로고    scopus 로고
    • The role of chemotherapy in the treatment of unresectable stage III and IV nonsmall cell lung cancer
    • Socinski MA. The role of chemotherapy in the treatment of unresectable stage III and IV nonsmall cell lung cancer. Respir Care Clin N Am 2003;9:207-36.
    • (2003) Respir Care Clin N Am , vol.9 , pp. 207-236
    • Socinski, M.A.1
  • 7
    • 0037037386 scopus 로고    scopus 로고
    • Platinum drugs in the treatment of non-small-cell lung cancer
    • Cosaert J, Quoix E. Platinum drugs in the treatment of non-small-cell lung cancer. Br J Cancer 2002;87:825-33.
    • (2002) Br J Cancer , vol.87 , pp. 825-833
    • Cosaert, J.1    Quoix, E.2
  • 8
    • 21144436938 scopus 로고    scopus 로고
    • Treatment of advanced non-small-cell lung cancer in the elderly: Results of an international expert panel
    • Gridelli C, Aapro M, Ardizzoni A, et al. Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel. J Clin Oncol 2005;23:3125-37.
    • (2005) J Clin Oncol , vol.23 , pp. 3125-3137
    • Gridelli, C.1    Aapro, M.2    Ardizzoni, A.3
  • 9
    • 2442661845 scopus 로고    scopus 로고
    • Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy
    • Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-97.
    • (2004) J Clin Oncol , vol.22 , pp. 1589-1597
    • Hanna, N.1    Shepherd, F.A.2    Fossella, F.V.3
  • 10
    • 22044445517 scopus 로고    scopus 로고
    • Erlotinib in previously treated non-small-cell lung cancer
    • Shepherd FA, Rodrigues RJ, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32.
    • (2005) N Engl J Med , vol.353 , pp. 123-132
    • Shepherd, F.A.1    Rodrigues, R.J.2    Ciuleanu, T.3
  • 11
    • 27544503230 scopus 로고    scopus 로고
    • Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
    • Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366:1527-37.
    • (2005) Lancet , vol.366 , pp. 1527-1537
    • Thatcher, N.1    Chang, A.2    Parikh, P.3
  • 12
    • 4444238981 scopus 로고    scopus 로고
    • Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC) [abstract 7010]
    • Gatzemeier U, Pluzanska A, Szczesna A, et al. Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC) [abstract 7010]. J Clin Oncol 2004;22:7010.
    • (2004) J Clin Oncol , vol.22 , pp. 7010
    • Gatzemeier, U.1    Pluzanska, A.2    Szczesna, A.3
  • 13
    • 1542503746 scopus 로고    scopus 로고
    • Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT1
    • Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT1. J Clin Oncol 2004;22:777-84.
    • (2004) J Clin Oncol , vol.22 , pp. 777-784
    • Giaccone, G.1    Herbst, R.S.2    Manegold, C.3
  • 14
    • 1542713370 scopus 로고    scopus 로고
    • Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 2
    • Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2. J Clin Oncol 2004;22:785-94.
    • (2004) J Clin Oncol , vol.22 , pp. 785-794
    • Herbst, R.S.1    Giaccone, G.2    Schiller, J.H.3
  • 15
    • 0026846928 scopus 로고    scopus 로고
    • The role of angiogenesis in tumor growth
    • Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol 2002;3:65-71.
    • (2002) Semin Cancer Biol , vol.3 , pp. 65-71
    • Folkman, J.1
  • 16
    • 0036780251 scopus 로고    scopus 로고
    • Clinical translation of angiogenesis inhibitors
    • Kerbel RS, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002;2:727-39.
    • (2002) Nat Rev Cancer , vol.2 , pp. 727-739
    • Kerbel, R.S.1    Folkman, J.2
  • 17
    • 0242637170 scopus 로고    scopus 로고
    • Targeting angiogenesis: A review of angiogenesis inhibitors in the treatment of lung cancer
    • Sridhar SS, Shepherd FA. Targeting angiogenesis: a review of angiogenesis inhibitors in the treatment of lung cancer. Lung Cancer 2003;42 Suppl 1:S81-91.
    • (2003) Lung Cancer , vol.42 , Issue.SUPPL. 1
    • Sridhar, S.S.1    Shepherd, F.A.2
  • 18
    • 0842329999 scopus 로고    scopus 로고
    • Angiogenesis inhibitors in clinical development; where are we now and where are we going?
    • Eskens FALM. Angiogenesis inhibitors in clinical development; where are we now and where are we going? Br J Cancer 2004;90:1-7.
    • (2004) Br J Cancer , vol.90 , pp. 1-7
    • Eskens, F.A.L.M.1
  • 19
    • 12244292196 scopus 로고    scopus 로고
    • Differentiation and definition of vascular-targeted therapies
    • Siemann DW, Bibby MC, Dark GG, et al. Differentiation and definition of vascular-targeted therapies. Clin Cancer Res 2005;11:416-20.
    • (2005) Clin Cancer Res , vol.11 , pp. 416-420
    • Siemann, D.W.1    Bibby, M.C.2    Dark, G.G.3
  • 21
    • 33745934672 scopus 로고    scopus 로고
    • Angiogenesis inhibitors in lung cancer: A promise fulfilled
    • Dy GK, Adjei AA. Angiogenesis inhibitors in lung cancer: a promise fulfilled. Clin Lung Cancer 2006;7 Suppl 4:S145-9.
    • (2006) Clin Lung Cancer , vol.7 , Issue.SUPPL. 4
    • Dy, G.K.1    Adjei, A.A.2
  • 22
    • 0037967272 scopus 로고    scopus 로고
    • Tumorigenesis and the angiogenic switch
    • Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3:401-10.
    • (2003) Nat Rev Cancer , vol.3 , pp. 401-410
    • Bergers, G.1    Benjamin, L.E.2
  • 23
    • 4143136640 scopus 로고    scopus 로고
    • Vascular endothelial growth factor: Basic science and clinical progress
    • Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004;25:581-611.
    • (2004) Endocr Rev , vol.25 , pp. 581-611
    • Ferrara, N.1
  • 24
    • 0037699954 scopus 로고    scopus 로고
    • The biology of VEGF and its receptors
    • Ferrara N, Gerber H-P, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76.
    • (2003) Nat Med , vol.9 , pp. 669-676
    • Ferrara, N.1    Gerber, H.-P.2    LeCouter, J.3
  • 25
    • 2942590261 scopus 로고    scopus 로고
    • Vascular endothelial growth factor as a target for anticancer therapy
    • Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 2004;9 Suppl 1:2-10.
    • (2004) Oncologist , vol.9 , Issue.SUPPL. 1 , pp. 2-10
    • Ferrara, N.1
  • 26
    • 1842328560 scopus 로고    scopus 로고
    • Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer
    • Volm M, Koomagi R, Mattern J. Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer. Int J Cancer 1997;74:64-8.
    • (1997) Int J Cancer , vol.74 , pp. 64-68
    • Volm, M.1    Koomagi, R.2    Mattern, J.3
  • 27
    • 0031966682 scopus 로고    scopus 로고
    • Vascular endothelial growth factor expression in non-small cell lung cancer: Prognostic significance in squamous cell carcinoma
    • Imoto H, Osaki T, Taga S, Ohgami A, Ichiyoshi Y, Yasumoto K. Vascular endothelial growth factor expression in non-small cell lung cancer: prognostic significance in squamous cell carcinoma. J Thorac Cardiovasc Surg 1998;115:1007-14.
    • (1998) J Thorac Cardiovasc Surg , vol.115 , pp. 1007-1014
    • Imoto, H.1    Osaki, T.2    Taga, S.3    Ohgami, A.4    Ichiyoshi, Y.5    Yasumoto, K.6
  • 28
    • 0034024352 scopus 로고    scopus 로고
    • Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small cell lung cancer
    • O'Byrne KJ, Koukourakis MI, Giatromanolaki A, et al. Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small cell lung cancer. Br J Cancer 2000;82:1427-32.
    • (2000) Br J Cancer , vol.82 , pp. 1427-1432
    • O'Byrne, K.J.1    Koukourakis, M.I.2    Giatromanolaki, A.3
  • 29
    • 0035155064 scopus 로고    scopus 로고
    • Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis
    • Han H, Silverman JF, Santucci TS, et al. Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis. Ann Surg Oncol 2001;8:72-9.
    • (2001) Ann Surg Oncol , vol.8 , pp. 72-79
    • Han, H.1    Silverman, J.F.2    Santucci, T.S.3
  • 30
    • 0035863288 scopus 로고    scopus 로고
    • Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small cell lung cancer
    • Yuan A, Yu CJ, Kuo SH, et al. Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small cell lung cancer. J Clin Oncol 2001;19:432-41.
    • (2001) J Clin Oncol , vol.19 , pp. 432-441
    • Yuan, A.1    Yu, C.J.2    Kuo, S.H.3
  • 31
    • 18244364180 scopus 로고    scopus 로고
    • A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma
    • Fontanini G, Faviana P, Lucchi M, et al. A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma. Br J Cancer 2002;86:558-63.
    • (2002) Br J Cancer , vol.86 , pp. 558-563
    • Fontanini, G.1    Faviana, P.2    Lucchi, M.3
  • 32
    • 3242700400 scopus 로고    scopus 로고
    • The prognostic significance of vascular endothelial growth factor levels in sera of non-small cell lung cancer patients
    • Kaya A, Ciledag A, Gulbay BE, et al. The prognostic significance of vascular endothelial growth factor levels in sera of non-small cell lung cancer patients. Respir Med 2004;98:632-6.
    • (2004) Respir Med , vol.98 , pp. 632-636
    • Kaya, A.1    Ciledag, A.2    Gulbay, B.E.3
  • 33
    • 19844380545 scopus 로고    scopus 로고
    • Role of serum vascular endothelial growth factor in the prediction of angiogenesis and prognosis for non-small cell lung cancer
    • Shimanuki Y, Takahashi K, Cui R, et al. Role of serum vascular endothelial growth factor in the prediction of angiogenesis and prognosis for non-small cell lung cancer. Lung 2005;183:29-42.
    • (2005) Lung , vol.183 , pp. 29-42
    • Shimanuki, Y.1    Takahashi, K.2    Cui, R.3
  • 34
    • 0037626575 scopus 로고    scopus 로고
    • Molecular mechanisms of angiogenesis in non-small cell lung cancer, and therapeutics targeting related molecules
    • Yano S, Nishioka Y, Goto H, Sone S. Molecular mechanisms of angiogenesis in non-small cell lung cancer, and therapeutics targeting related molecules. Cancer Sci 2003;94:479-85.
    • (2003) Cancer Sci , vol.94 , pp. 479-485
    • Yano, S.1    Nishioka, Y.2    Goto, H.3    Sone, S.4
  • 35
    • 3843135260 scopus 로고    scopus 로고
    • Enhancement of pleural dissemination and lymph node metastasis of intrathoracic lung cancer cells by vascular endothelial growth factors (VEGFs)
    • Ishii H, Yazawa T, Sato H, et al. Enhancement of pleural dissemination and lymph node metastasis of intrathoracic lung cancer cells by vascular endothelial growth factors (VEGFs). Lung Cancer 2004;45:325-37.
    • (2004) Lung Cancer , vol.45 , pp. 325-337
    • Ishii, H.1    Yazawa, T.2    Sato, H.3
  • 36
    • 0000748868 scopus 로고
    • The effect of antibody to vascular endothelial growth factor and cisplatin on the growth of lung tumors in nude mice [abstract 2906]
    • Kabbinavar FF, Wong JT, Ayala RE, et al. The effect of antibody to vascular endothelial growth factor and cisplatin on the growth of lung tumors in nude mice [abstract 2906]. Proc Am Assoc Cancer Res 1995;36:488.
    • (1995) Proc Am Assoc Cancer Res , vol.36 , pp. 488
    • Kabbinavar, F.F.1    Wong, J.T.2    Ayala, R.E.3
  • 37
    • 0034665166 scopus 로고    scopus 로고
    • Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice
    • Brekken RA, Overholser JP, Stastny VA, Waltenberger J, Minna JD, Thorpe PE. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res 2000;60:5117-24.
    • (2000) Cancer Res , vol.60 , pp. 5117-5124
    • Brekken, R.A.1    Overholser, J.P.2    Stastny, V.A.3    Waltenberger, J.4    Minna, J.D.5    Thorpe, P.E.6
  • 38
    • 9144265679 scopus 로고    scopus 로고
    • Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects
    • Abdollahi A, Lipson KE, Sckell A, et al. Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects. Cancer Res 2003;63:8890-8.
    • (2003) Cancer Res , vol.63 , pp. 8890-8898
    • Abdollahi, A.1    Lipson, K.E.2    Sckell, A.3
  • 39
    • 2442708026 scopus 로고    scopus 로고
    • Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor
    • Sun J, Blaskovich MA, Jain RK, et al. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor. Cancer Res 2004;64:3586-92.
    • (2004) Cancer Res , vol.64 , pp. 3586-3592
    • Sun, J.1    Blaskovich, M.A.2    Jain, R.K.3
  • 40
    • 12344263868 scopus 로고    scopus 로고
    • KRN633: A selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase that suppresses tumor angiogenesis and growth
    • Nakamura K, Yamamoto A, Kamishohara M, et al. KRN633: a selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase that suppresses tumor angiogenesis and growth. Mol Cancer Ther 2004;3:1639-49.
    • (2004) Mol Cancer Ther , vol.3 , pp. 1639-1649
    • Nakamura, K.1    Yamamoto, A.2    Kamishohara, M.3
  • 41
    • 3042803907 scopus 로고    scopus 로고
    • A novel low molecular weight VEGF receptor-binding antagonist, VGA1102, inhibits the function of VEGF and in vivo tumor growth
    • Ueda Y, Yamagishi T, Samata K, et al. A novel low molecular weight VEGF receptor-binding antagonist, VGA1102, inhibits the function of VEGF and in vivo tumor growth. Cancer Chemother Pharmacol 2004;54:16-24.
    • (2004) Cancer Chemother Pharmacol , vol.54 , pp. 16-24
    • Ueda, Y.1    Yamagishi, T.2    Samata, K.3
  • 42
    • 0034655246 scopus 로고    scopus 로고
    • Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ
    • Takayama K, Ueno H, Nakanishi Y, et al. Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ. Cancer Res 2000;60:2169-77.
    • (2000) Cancer Res , vol.60 , pp. 2169-2177
    • Takayama, K.1    Ueno, H.2    Nakanishi, Y.3
  • 43
    • 0036006171 scopus 로고    scopus 로고
    • Vascular endothelial growth factor (VEGF), a survival factor for tumour cells: Implications for anti-angiogenic therapy
    • Harmey JH, Bouchier-Hayes D. Vascular endothelial growth factor (VEGF), a survival factor for tumour cells: implications for anti-angiogenic therapy. Bioessays 2002;24:280-3.
    • (2002) Bioessays , vol.24 , pp. 280-283
    • Harmey, J.H.1    Bouchier-Hayes, D.2
  • 44
    • 20544471876 scopus 로고    scopus 로고
    • Combined analysis of efficacy: The addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer
    • Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005;23:3706-12.
    • (2005) J Clin Oncol , vol.23 , pp. 3706-3712
    • Kabbinavar, F.F.1    Hambleton, J.2    Mass, R.D.3    Hurwitz, H.I.4    Bergsland, E.5    Sarkar, S.6
  • 45
    • 2542561964 scopus 로고    scopus 로고
    • Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
    • Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
    • (2004) N Engl J Med , vol.350 , pp. 2335-2342
    • Hurwitz, H.1    Fehrenbacher, L.2    Novotny, W.3
  • 46
    • 28044467635 scopus 로고    scopus 로고
    • Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of SU11248 in patients (pts) following failure of imatinib for metastatic GIST [abstract 4000]
    • Demetri GD, van Oosterom AT, Blackstein M, et al. Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of SU11248 in patients (pts) following failure of imatinib for metastatic GIST [abstract 4000]. J Clin Oncol 2005;23:308S.
    • (2005) J Clin Oncol , vol.23
    • Demetri, G.D.1    van Oosterom, A.T.2    Blackstein, M.3
  • 47
    • 23844558595 scopus 로고    scopus 로고
    • Randomized phase III trial of the raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC) [abstract LBA4510]
    • Escudier B, Szczylik C, Eisen T et al. Randomized phase III trial of the raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC) [abstract LBA4510]. J Clin Oncol 2005;23:380S.
    • (2005) J Clin Oncol , vol.23
    • Escudier, B.1    Szczylik, C.2    Eisen, T.3
  • 48
    • 21244481589 scopus 로고    scopus 로고
    • High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the eastern cooperative oncology group (ECOG) study E3200 [abstract 2]
    • Giantonio BJ, Catalano PJ, Meropol NJ, et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the eastern cooperative oncology group (ECOG) study E3200 [abstract 2]. J Clin Oncol 2005;23:1S.
    • (2005) J Clin Oncol , vol.23
    • Giantonio, B.J.1    Catalano, P.J.2    Meropol, N.J.3
  • 49
    • 0030856731 scopus 로고    scopus 로고
    • Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders
    • Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593-9.
    • (1997) Cancer Res , vol.57 , pp. 4593-4599
    • Presta, L.G.1    Chen, H.2    O'Connor, S.J.3
  • 50
    • 2942526896 scopus 로고    scopus 로고
    • Non-small cell lung cancer and antiangiogenic therapy: What can be expected of bevacizumab?
    • Herbst RS, Sandler AB. Non-small cell lung cancer and antiangiogenic therapy: what can be expected of bevacizumab? Oncologist 2004;9:19-26.
    • (2004) Oncologist , vol.9 , pp. 19-26
    • Herbst, R.S.1    Sandler, A.B.2
  • 51
    • 0042343801 scopus 로고    scopus 로고
    • A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer
    • Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-34.
    • (2003) N Engl J Med , vol.349 , pp. 427-434
    • Yang, J.C.1    Haworth, L.2    Sherry, R.M.3
  • 52
    • 33644984682 scopus 로고    scopus 로고
    • First-line bevacizumab and paclitaxel in patients with locally recurrent or metastatic breast cancer: A randomized, phase III trial coordinated by the Eastern Cooperative Oncology Group (E2100) [abstract 275]
    • Miller K, Wang M, Gralow J, et al. First-line bevacizumab and paclitaxel in patients with locally recurrent or metastatic breast cancer: a randomized, phase III trial coordinated by the Eastern Cooperative Oncology Group (E2100) [abstract 275]. Eur J Cancer Suppl 2005;3:77.
    • (2005) Eur J Cancer Suppl , vol.3 , pp. 77
    • Miller, K.1    Wang, M.2    Gralow, J.3
  • 53
    • 2942657615 scopus 로고    scopus 로고
    • Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer
    • Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22:2184-91.
    • (2004) J Clin Oncol , vol.22 , pp. 2184-2191
    • Johnson, D.H.1    Fehrenbacher, L.2    Novotny, W.F.3
  • 54
    • 22144471081 scopus 로고    scopus 로고
    • Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC # 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) trial - E4599 [abstract LBA4]
    • Sandler AB, Gray R, Brahmer J, et al. Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC # 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) trial - E4599 [abstract LBA4]. J Clin Oncol 2005;23:2S.
    • (2005) J Clin Oncol , vol.23
    • Sandler, A.B.1    Gray, R.2    Brahmer, J.3
  • 55
    • 4944249117 scopus 로고    scopus 로고
    • BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
    • Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109.
    • (2004) Cancer Res , vol.64 , pp. 7099-7109
    • Wilhelm, S.M.1    Carter, C.2    Tang, L.3
  • 56
    • 28044434570 scopus 로고    scopus 로고
    • A phase I study of BAY 43-9006 and gefitinib in patients with refractory or recurrent non-small-cell lung cancer (NSCLC) [abstract 3067]
    • Adjei AA, Mandrekar S, Marks RS, et al. A phase I study of BAY 43-9006 and gefitinib in patients with refractory or recurrent non-small-cell lung cancer (NSCLC) [abstract 3067]. J Clin Oncol 2005;23:208S.
    • (2005) J Clin Oncol , vol.23
    • Adjei, A.A.1    Mandrekar, S.2    Marks, R.S.3
  • 57
    • 33748913369 scopus 로고    scopus 로고
    • Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma [abstract 7002]
    • Gatzemeier U, Blumenschein G, Fosella F, et al. Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma [abstract 7002]. J Clin Oncol 2006;24:7002.
    • (2006) J Clin Oncol , vol.24 , pp. 7002
    • Gatzemeier, U.1    Blumenschein, G.2    Fosella, F.3
  • 58
    • 78650874372 scopus 로고    scopus 로고
    • SU11248 inhibits KIT and platelet-derived growth factor receptor β in preclinical models of human small cell lung cancer
    • Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. SU11248 inhibits KIT and platelet-derived growth factor receptor β in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003;2:471-8.
    • (2003) Mol Cancer Ther , vol.2 , pp. 471-478
    • Abrams, T.J.1    Lee, L.B.2    Murray, L.J.3    Pryer, N.K.4    Cherrington, J.M.5
  • 59
    • 0038204144 scopus 로고    scopus 로고
    • SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo
    • O'Farrell AM, Abrams TJ, Yuen HA, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003;101:3597-605.
    • (2003) Blood , vol.101 , pp. 3597-3605
    • O'Farrell, A.M.1    Abrams, T.J.2    Yuen, H.A.3
  • 60
    • 12444297983 scopus 로고    scopus 로고
    • The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels
    • Osusky KL, Hallahan DE, Fu A, Ye F, Shyr Y, Geng L. The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels. Angiogenesis 2004;7:225-33.
    • (2004) Angiogenesis , vol.7 , pp. 225-233
    • Osusky, K.L.1    Hallahan, D.E.2    Fu, A.3    Ye, F.4    Shyr, Y.5    Geng, L.6
  • 61
    • 12244301581 scopus 로고    scopus 로고
    • In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship
    • Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:327-37.
    • (2003) Clin Cancer Res , vol.9 , pp. 327-337
    • Mendel, D.B.1    Laird, A.D.2    Xin, X.3
  • 62
    • 0041672482 scopus 로고    scopus 로고
    • SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models
    • Schueneman AJ, Himmelfarb E, Geng L, et al. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res 2003;63:4009-16.
    • (2003) Cancer Res , vol.63 , pp. 4009-4016
    • Schueneman, A.J.1    Himmelfarb, E.2    Geng, L.3
  • 63
    • 33644833910 scopus 로고    scopus 로고
    • Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma
    • Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:16-24.
    • (2006) J Clin Oncol , vol.24 , pp. 16-24
    • Motzer, R.J.1    Michaelson, M.D.2    Redman, B.G.3
  • 64
    • 0034655182 scopus 로고    scopus 로고
    • PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration
    • Wood JM, Bold G, Buchdunger E, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000;60:2178-89.
    • (2000) Cancer Res , vol.60 , pp. 2178-2189
    • Wood, J.M.1    Bold, G.2    Buchdunger, E.3
  • 65
    • 0034016273 scopus 로고    scopus 로고
    • Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation
    • Yano S, Herbst RS, Shinohara H, et al. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation. Clin Cancer Res 2000;6:957-65.
    • (2000) Clin Cancer Res , vol.6 , pp. 957-965
    • Yano, S.1    Herbst, R.S.2    Shinohara, H.3
  • 66
    • 23044432756 scopus 로고    scopus 로고
    • Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer
    • Thomas AL, Morgan B, Horsfield MA, et al. Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. J Clin Oncol 2005;23:4162-71.
    • (2005) J Clin Oncol , vol.23 , pp. 4162-4171
    • Thomas, A.L.1    Morgan, B.2    Horsfield, M.A.3
  • 67
    • 23844548194 scopus 로고    scopus 로고
    • A randomized, double-blind, placebo-controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1) [abstract LBA3]
    • Hecht JR, Trarbach T, Jaeger E, et al. A randomized, double-blind, placebo-controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1) [abstract LBA3]. J Clin Oncol 2005;23:2S.
    • (2005) J Clin Oncol , vol.23
    • Hecht, J.R.1    Trarbach, T.2    Jaeger, E.3
  • 68
    • 33749637207 scopus 로고    scopus 로고
    • Results of an interim analysis of a multinational randomized, double-blind, phase III study in patients (pts) with previously treated metastatic colorectal cancer receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo (CONFIRM-2) [abstract 3508]
    • Koehne C, Bajetta E, Lin E, et al. Results of an interim analysis of a multinational randomized, double-blind, phase III study in patients (pts) with previously treated metastatic colorectal cancer receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo (CONFIRM-2) [abstract 3508]. J Clin Oncol 2006;24:3508.
    • (2006) J Clin Oncol , vol.24 , pp. 3508
    • Koehne, C.1    Bajetta, E.2    Lin, E.3
  • 69
    • 32044469735 scopus 로고    scopus 로고
    • The effect of AMG 706, a novel multi-kinase inhibitor, on vascular permeability and blood flow as assessed by dynamic contrast enhanced magnetic resonance imaging in an in vivo preclinical tumor model [abstract 3134]
    • Jackson E, Esparza-Coss E, Bankson JA, et al. The effect of AMG 706, a novel multi-kinase inhibitor, on vascular permeability and blood flow as assessed by dynamic contrast enhanced magnetic resonance imaging in an in vivo preclinical tumor model [abstract 3134]. J Clin Oncol 2005;23:225S.
    • (2005) J Clin Oncol , vol.23
    • Jackson, E.1    Esparza-Coss, E.2    Bankson, J.A.3
  • 70
    • 10744222964 scopus 로고    scopus 로고
    • Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy
    • Beebe JS, Jani JP, Knauth E, et al. Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy. Cancer Res 2003;63:7301-9.
    • (2003) Cancer Res , vol.63 , pp. 7301-7309
    • Beebe, J.S.1    Jani, J.P.2    Knauth, E.3
  • 71
    • 34247472705 scopus 로고    scopus 로고
    • Phase I trial of oral CP-547,632 (VEGFR2) in combination with paclitaxel (P) and carboplatin (C) in advanced non-small cell lung cancer (NSCLC) [abstract 3014]
    • Cohen RB, Simon G, Langer CJ, et al. Phase I trial of oral CP-547,632 (VEGFR2) in combination with paclitaxel (P) and carboplatin (C) in advanced non-small cell lung cancer (NSCLC) [abstract 3014]. J Clin Oncol 2004;22:14S.
    • (2004) J Clin Oncol , vol.22
    • Cohen, R.B.1    Simon, G.2    Langer, C.J.3
  • 72
    • 20144370978 scopus 로고    scopus 로고
    • AZD2171: A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer
    • Wedge SR, Kendrew J, Hennequin LF, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 2005;65:4389-400.
    • (2005) Cancer Res , vol.65 , pp. 4389-4400
    • Wedge, S.R.1    Kendrew, J.2    Hennequin, L.F.3
  • 73
    • 33751414107 scopus 로고    scopus 로고
    • Final results of a phase I study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor receptors (VEGFR), in combination with carboplatin (C) + paclitaxel (T) in patients with advanced non-small cell lung cancer (NSCLC): A study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) [abstract 3054]
    • Laurie SA, Arnold A, Gauthier I, et al. Final results of a phase I study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor receptors (VEGFR), in combination with carboplatin (C) + paclitaxel (T) in patients with advanced non-small cell lung cancer (NSCLC): a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) [abstract 3054]. J Clin Oncol 2006;24:3054.
    • (2006) J Clin Oncol , vol.24 , pp. 3054
    • Laurie, S.A.1    Arnold, A.2    Gauthier, I.3
  • 74
    • 0037934449 scopus 로고    scopus 로고
    • Regression of established tumors and metastases by potent vascular endothelial growth factor blockade
    • Huang J, Frischer JS, Serur A, et al. Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc Natl Acad Sci U S A 2003;100:7785-90.
    • (2003) Proc Natl Acad Sci U S A , vol.100 , pp. 7785-7790
    • Huang, J.1    Frischer, J.S.2    Serur, A.3
  • 75
    • 33746316839 scopus 로고    scopus 로고
    • Phase II study of carboplatin, irinotecan and thalidomide in patients with advanced non-small cell lung cancer (NSCLC) [abstract 7132]
    • Miller AA, Case D, Atkins J, Giguere J. Phase II study of carboplatin, irinotecan and thalidomide in patients with advanced non-small cell lung cancer (NSCLC) [abstract 7132]. J Clin Oncol 2004;22:649S.
    • (2004) J Clin Oncol , vol.22
    • Miller, A.A.1    Case, D.2    Atkins, J.3    Giguere, J.4
  • 76
    • 34247529580 scopus 로고    scopus 로고
    • Flora DB, Kleykamp B, Knapp M, Shukla R, Jazieh AR. A phase II trial of thalidomide (T), irinotecan (I) and gemcitabine (G) in chemonaive patients (pts) with advanced non-small cell lung cancer (NSCLC) [abstract 7258]. J Clin Oncol 2004;22:680-S.
    • Flora DB, Kleykamp B, Knapp M, Shukla R, Jazieh AR. A phase II trial of thalidomide (T), irinotecan (I) and gemcitabine (G) in chemonaive patients (pts) with advanced non-small cell lung cancer (NSCLC) [abstract 7258]. J Clin Oncol 2004;22:680-S.
  • 77
    • 0033818695 scopus 로고    scopus 로고
    • Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells
    • Ciardiello F, Bianco R, Damiano V, et al. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res 2000;6:3739-47.
    • (2000) Clin Cancer Res , vol.6 , pp. 3739-3747
    • Ciardiello, F.1    Bianco, R.2    Damiano, V.3
  • 78
    • 17944370631 scopus 로고    scopus 로고
    • Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors
    • Shaheen RM, Ahmad SA, Liu W, et al. Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors. Br J Cancer 2001;85:584-9.
    • (2001) Br J Cancer , vol.85 , pp. 584-589
    • Shaheen, R.M.1    Ahmad, S.A.2    Liu, W.3
  • 79
    • 0036252329 scopus 로고    scopus 로고
    • Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model
    • Jung YD, Mansfield PF, Akagi M, et al. Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model. Eur J Cancer 2002;38:1133-40.
    • (2002) Eur J Cancer , vol.38 , pp. 1133-1140
    • Jung, Y.D.1    Mansfield, P.F.2    Akagi, M.3
  • 80
    • 5044236157 scopus 로고    scopus 로고
    • Epidermal growth factor receptor in tumor angiogenesis
    • viii
    • Ellis LM. Epidermal growth factor receptor in tumor angiogenesis. Hematol Oncol Clin North Am 2004;18:1007-21, viii.
    • (2004) Hematol Oncol Clin North Am , vol.18 , pp. 1007-1021
    • Ellis, L.M.1
  • 81
    • 28044433677 scopus 로고    scopus 로고
    • Epidermal growth factor receptor and angiogenesis: Opportunities for combined anticancer strategies
    • van Cruijsen H, Giaccone G, Hoekman K. Epidermal growth factor receptor and angiogenesis: opportunities for combined anticancer strategies. Int J Cancer 2005;117:883-8.
    • (2005) Int J Cancer , vol.117 , pp. 883-888
    • van Cruijsen, H.1    Giaccone, G.2    Hoekman, K.3
  • 82
    • 1242270612 scopus 로고    scopus 로고
    • Acquired resistance to EGFR inhibitors: Mechanisms and prevention strategies
    • Viloria-Petit AM, Kerbel RS. Acquired resistance to EGFR inhibitors: mechanisms and prevention strategies. Int J Radiat Oncol Biol Phys 2004;58:914-26.
    • (2004) Int J Radiat Oncol Biol Phys , vol.58 , pp. 914-926
    • Viloria-Petit, A.M.1    Kerbel, R.S.2
  • 83
    • 34247518783 scopus 로고    scopus 로고
    • Preclinical activity of AEE788, a potent new inhibitor of the ErbB and VEGF receptor tyrosine kinases: Discovery and in vitro profile of AEE788 [abstract A118]
    • Caravatti G, Bold G, Bruggen J, et al. Preclinical activity of AEE788, a potent new inhibitor of the ErbB and VEGF receptor tyrosine kinases: discovery and in vitro profile of AEE788 [abstract A118]. Clin Cancer Res 2003;9:16.
    • (2003) Clin Cancer Res , vol.9 , pp. 16
    • Caravatti, G.1    Bold, G.2    Bruggen, J.3
  • 84
    • 34247518783 scopus 로고    scopus 로고
    • Preclinical activity of AEE788, a potent new inhibitor of the ErbB and VEGF receptor tyrosine kinases: In vivo profile of AEE788 [abstract A87]
    • Traxler P, Allegrini PR, Brandt R, et al. Preclinical activity of AEE788, a potent new inhibitor of the ErbB and VEGF receptor tyrosine kinases: in vivo profile of AEE788 [abstract A87]. Clin Cancer Res 2003;9 Suppl 1:16.
    • (2003) Clin Cancer Res , vol.9 , Issue.SUPPL. 1 , pp. 16
    • Traxler, P.1    Allegrini, P.R.2    Brandt, R.3
  • 85
    • 28044436878 scopus 로고    scopus 로고
    • A phase I study of AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases, in recurrent GBM patients [abstract 3063]
    • Reardon D, Cloughesy T, Conrad C, et al. A phase I study of AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases, in recurrent GBM patients [abstract 3063]. Proc Am Soc Clin Oncol 2005;24:3063.
    • (2005) Proc Am Soc Clin Oncol , vol.24 , pp. 3063
    • Reardon, D.1    Cloughesy, T.2    Conrad, C.3
  • 86
    • 0037386774 scopus 로고    scopus 로고
    • Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase
    • Ciardiello F, Caputo R, Damiano V, et al. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 2003;9:1546-56.
    • (2003) Clin Cancer Res , vol.9 , pp. 1546-1556
    • Ciardiello, F.1    Caputo, R.2    Damiano, V.3
  • 87
    • 0037102369 scopus 로고    scopus 로고
    • ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration
    • Wedge SR, Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002;62:4645-55.
    • (2002) Cancer Res , vol.62 , pp. 4645-4655
    • Wedge, S.R.1    Ogilvie, D.J.2    Dukes, M.3
  • 88
    • 10844285939 scopus 로고    scopus 로고
    • Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib ("Iressa")-sensitive and resistant xenograft models
    • Taguchi F, Koh Y, Koizumi F, Tamura T, Saijo N, Nishio K. Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib ("Iressa")-sensitive and resistant xenograft models. Cancer Sci 2004;95:984-9.
    • (2004) Cancer Sci , vol.95 , pp. 984-989
    • Taguchi, F.1    Koh, Y.2    Koizumi, F.3    Tamura, T.4    Saijo, N.5    Nishio, K.6
  • 89
    • 23844544081 scopus 로고    scopus 로고
    • Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors
    • Holden SN, Eckhardt SG, Basser R, et al. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol 2005;16:1391-7.
    • (2005) Ann Oncol , vol.16 , pp. 1391-1397
    • Holden, S.N.1    Eckhardt, S.G.2    Basser, R.3
  • 90
    • 29244480558 scopus 로고    scopus 로고
    • A randomized, placebo-controlled phase II trial of ZD6474 plus docetaxel, in patients with NSCLC [abstract 3023]
    • Heymach JV, Johnson BE, Rowbottom JA, et al. A randomized, placebo-controlled phase II trial of ZD6474 plus docetaxel, in patients with NSCLC [abstract 3023]. J Clin Oncol 2005;23:197S.
    • (2005) J Clin Oncol , vol.23
    • Heymach, J.V.1    Johnson, B.E.2    Rowbottom, J.A.3
  • 91
    • 21244501441 scopus 로고    scopus 로고
    • Preliminary phase II safety evaluation of ZD6474, in combination with carboplatin and paclitaxel, as 1st-line treatment in patients with NSCLC [abstract 7102]
    • Johnson BE, Ma P, West H, et al. Preliminary phase II safety evaluation of ZD6474, in combination with carboplatin and paclitaxel, as 1st-line treatment in patients with NSCLC [abstract 7102]. J Clin Oncol 2005;23:645S.
    • (2005) J Clin Oncol , vol.23
    • Johnson, B.E.1    Ma, P.2    West, H.3
  • 92
    • 33644982526 scopus 로고    scopus 로고
    • Results of a randomized, double-blind phase II trial of ZD6474 versus gefitinib in patients with NSCLC [abstract 1124]
    • Ranson M, Bodkin D, Govindan R, et al. Results of a randomized, double-blind phase II trial of ZD6474 versus gefitinib in patients with NSCLC [abstract 1124]. Eur J Cancer Suppl 2005;3:324.
    • (2005) Eur J Cancer Suppl , vol.3 , pp. 324
    • Ranson, M.1    Bodkin, D.2    Govindan, R.3
  • 93
    • 20244381389 scopus 로고    scopus 로고
    • Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer
    • Herbst RS, Johnson DH, Mininberg E, et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005;23:2544-55.
    • (2005) J Clin Oncol , vol.23 , pp. 2544-2555
    • Herbst, R.S.1    Johnson, D.H.2    Mininberg, E.3
  • 94
    • 34247467122 scopus 로고    scopus 로고
    • A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab (Avastin®) in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride (Tarceva®) compared with chemotherapy alone for treatment of recurrent or refractory non-small-cell lung cancer [abstract 53]
    • Herbst RS, Fehrenbacher L, Belani CP, et al. A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab (Avastin®) in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride (Tarceva®) compared with chemotherapy alone for treatment of recurrent or refractory non-small-cell lung cancer [abstract 53]. Eur J Cancer Suppl 2006;4:20.
    • (2006) Eur J Cancer Suppl , vol.4 , pp. 20
    • Herbst, R.S.1    Fehrenbacher, L.2    Belani, C.P.3
  • 95
    • 33845705108 scopus 로고    scopus 로고
    • Phase I evaluation of AZD2171, a highly potent, selective VEGFR signaling inhibitor, in combination with gefitinib, in patients with advanced tumors [abstract 3017]
    • Van Cruijsen H, Voest EE, Van Herpen CM, et al. Phase I evaluation of AZD2171, a highly potent, selective VEGFR signaling inhibitor, in combination with gefitinib, in patients with advanced tumors [abstract 3017]. J Clin Oncol 2006;24:3017.
    • (2006) J Clin Oncol , vol.24 , pp. 3017
    • Van Cruijsen, H.1    Voest, E.E.2    Van Herpen, C.M.3
  • 96
    • 0036531949 scopus 로고    scopus 로고
    • What do oncogenic mutations have to do with angiogenesis/vascular dependence of tumors?
    • Rak J, Yu JL, Kerbel RS, Coomber BL. What do oncogenic mutations have to do with angiogenesis/vascular dependence of tumors? Cancer Res 2002;62:1931-4.
    • (2002) Cancer Res , vol.62 , pp. 1931-1934
    • Rak, J.1    Yu, J.L.2    Kerbel, R.S.3    Coomber, B.L.4
  • 97
    • 0035887463 scopus 로고    scopus 로고
    • Low-dose chemotherapy combined with an anti-angiogenic drug reduces human glioma growth in vivo
    • Bello L, Carrabba G, Giussani C, et al. Low-dose chemotherapy combined with an anti-angiogenic drug reduces human glioma growth in vivo. Cancer Res 2001;61:7501-6.
    • (2001) Cancer Res , vol.61 , pp. 7501-7506
    • Bello, L.1    Carrabba, G.2    Giussani, C.3
  • 98
    • 0037093209 scopus 로고    scopus 로고
    • Antitumor and anti-angiogenic effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water
    • Man S, Bocci G, Francia G, et al. Antitumor and anti-angiogenic effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res 2002;62:2731-5.
    • (2002) Cancer Res , vol.62 , pp. 2731-2735
    • Man, S.1    Bocci, G.2    Francia, G.3
  • 99
    • 2942615257 scopus 로고    scopus 로고
    • The anti-angiogenic basis of metronomic chemotherapy
    • Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004;4:423-36.
    • (2004) Nat Rev Cancer , vol.4 , pp. 423-436
    • Kerbel, R.S.1    Kamen, B.A.2
  • 100
    • 0031753296 scopus 로고    scopus 로고
    • Treatment of non-small-cell lung cancer with prolonged oral etoposide
    • Kakolyris S, Samonis G, Koukourakis M, et al. Treatment of non-small-cell lung cancer with prolonged oral etoposide. Am J Clin Oncol 1998;21:505-8.
    • (1998) Am J Clin Oncol , vol.21 , pp. 505-508
    • Kakolyris, S.1    Samonis, G.2    Koukourakis, M.3
  • 101
    • 34247509357 scopus 로고    scopus 로고
    • Prospective correlative assessment of biomarkers in E4599 randomized phase II/III trial of carboplatin and paclitaxel ± bevacizumab in advanced non-small cell lung cancer (NSCLC) [abstract 7027]
    • Dowlati A, Gray R, Johnson DH, et al. Prospective correlative assessment of biomarkers in E4599 randomized phase II/III trial of carboplatin and paclitaxel ± bevacizumab in advanced non-small cell lung cancer (NSCLC) [abstract 7027]. J Clin Oncol 2006;24:7027.
    • (2006) J Clin Oncol , vol.24 , pp. 7027
    • Dowlati, A.1    Gray, R.2    Johnson, D.H.3
  • 102
    • 34247471304 scopus 로고    scopus 로고
    • Molecular tumor characteristics and response to bevacizumab plus irinotecan/5-fluorouracil/leucovorin in metastatic colorectal cancer [abstract 150]
    • Koeppen HKW, Ince WL, Holmgren E, et al. Molecular tumor characteristics and response to bevacizumab plus irinotecan/5-fluorouracil/leucovorin in metastatic colorectal cancer [abstract 150]. Eur J Cancer 2004;2:48.
    • (2004) Eur J Cancer , vol.2 , pp. 48
    • Koeppen, H.K.W.1    Ince, W.L.2    Holmgren, E.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.